NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Accuray Incorporated (ARAY) Stock Analysis

Accuray Incorporated (ARAY) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ARAY

$0.14

−$0.00 (−3.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARAY with… →

ARAY Key Statistics

As of Oct 21, 2026
Trading
Open
$0.15
Previous Close
$0.14
Day's Range
0.13–0.15
52-Week Range
0.13–1.65
Volume
4.51M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$16.36M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
29.49
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.40
Financials (FY)
Revenue (FY)
$458.51M+2.68%
Net Income (FY)
−$1.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
119.44M
1-Year Return
−91.49%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
7.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ARAY closed at $0.14, −91.49% over 1 year.

Accuray Incorporated (ARAY) has a market capitalization of $16.36M.

In fiscal 2025, ARAY reported revenue of $458.51M.

ARAY Stock Return by Calendar Year

Accuray Incorporated (ARAY) 10-year return: what $10,000 became

1 year
$10,000 $851
−91.49%
5 years
$10,000 $337
−96.63%
10 years
$10,000 $256
−97.44%

If you had invested $10,000 in Accuray Incorporated (ARAY) 10 years ago, at the close on October 21, 2016, it would have been worth $256 at the close on October 21, 2026: −97.44% in total, −30.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−83.29%
2025−58.59%
2024−30.04%
2023+35.41%
2022−56.18%
2021+14.39%
2020+47.87%
2019−17.30%
2018−20.70%
2017−6.52%
2016 (partial year)−15.60%

As of October 21, 2026.

ARAY Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$458.51M−$1.59M−0.3%
2024$446.55M−$15.55M−3.5%
2023$447.61M−$9.28M−2.1%
2022$429.91M−$5.35M−1.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$458.51M$146.97M$7.84M−$1.59M−0.3%
2024$446.55M$142.92M$504.00K−$15.55M−3.5%
2023$447.61M$153.96M$2.38M−$9.28M−2.1%
2022$429.91M$159.96M$8.15M−$5.35M−1.2%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

ARAY Valuation vs Medical Devices Median

Median of 145 stocks
MetricARAYMedical Devices medianvs median
P/S ratio0.042.530.0x the median
Profit margin−12.24%−14.78%2.5 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Accuray Incorporated (ARAY) at $16.36M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 809.

The 52-week range on file runs from $0.13 to $1.65. ARAY last closed at $0.14 on October 21, 2026. That is $0.00 (−3.52%) against the previous close. The latest close sits 2.7% above that 52-week low.

Financial Health

In fiscal 2025, Accuray Incorporated reported revenue of $458.51M. That is +2.68% against the prior fiscal year, when revenue was $446.55M. The same year closed with a net loss of $1.59M. Profit margin runs at −12.24%. That is 2.5 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.4.

Across the 4 fiscal years on file, revenue moves from $429.91M in 2022 to $458.51M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 29.49. The price-to-sales ratio is 0.04. On price-to-sales that is 0 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −91.49%. Across 10 years the annualized return works out at −30.68%. Beta against the wider market is reported at 1.42. Daily returns over the trailing 10 years annualize to a volatility of 70.17%.

Growth & Income

No dividend is on file for ARAY.

The strongest complete calendar year on file is 2020 at +47.87%; the weakest is 2025 at −58.59%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −83.29%.

Peer Comparison

Accuray Incorporated (ARAY) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Accuray Incorporated ARAY $16.36M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Accuray Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Accuray Incorporated

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Visit website →